Navigation Links
LX4211 Achieves Positive Results in Type 2 Diabetes Patients with Renal Impairment
Date:10/1/2013

THE WOODLANDS, Texas, Oct. 1, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that LX4211, a first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), successfully met the primary endpoint of reducing post-prandial glucose, in a study of patients with type 2 diabetes and moderate to severe renal impairment.  Reducing elevated post-prandial glucose, high blood sugar levels after meals, is a key objective of diabetes therapy.

In a placebo-controlled, proof-of-concept study, LX4211 provided clinically meaningful and statistically significant reductions (p<0.05) in post-prandial glucose in diabetes patients with moderate to severe renal impairment (Stage 3 and 4 kidney disease). Importantly, these effects were maintained in a sub-group with the most advanced renal impairment, pre-defined as those with glomerular filtration rate (GFR) less than 45 ml/min/1.73 m2. LX4211 also produced significant elevations in GLP-1, a hormone involved in control of glucose and appetite.

Renal impairment occurs in approximately 30% of patients with type 2 diabetes and represents a major unmet medical need with limited treatment options.  LX4211's inhibition of SGLT1 in the gastrointestinal (GI) tract, reducing glucose absorption and triggering GLP-1 secretion, offers the potential for treating this medically challenging population with compromised kidney function.  In previous Phase 2 studies, LX4211 improved glycemic control in patients with type 2 diabetes with normal renal function.

"Our hypothesis was that LX4211 would improve glycemic control even in patients with the greatest degree of renal impairment due to its inhibition of SGLT1 in the GI tract," said Pablo Lapuerta, M.D., Lexicon's c
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
2. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
3. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
4. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
5. LX4211 Phase 2b Results Presented At American Heart Association Annual Conference
6. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
7. Lexicon Presents Data at the American Diabetes Association Meeting On Blood Pressure Reduction and Weight Loss In Clinical Trial of LX4211
8. Greenville Hospital System Achieves Dramatic Improvement in Hand Hygiene Compliance Rates Using New Technology from DebMed®
9. Acuo Technologies Grows European Business and Achieves Successful Connectathon Results in Bern, Switzerland
10. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
11. QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... of the "Infectious Disease Diagnostics Market by Product, ... report to their offering. , The ... CAGR of 7.9% to reach $18,156.2 million by 2019 ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... Diagnostics Market by Allergen Source, Product & by End User ... The global allergy diagnostics market is valued ... at a CAGR of 12.67%, to reach $2,230.72 million by ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "X-Ray Detectors Market by Detector Type, Applications & by FPD ... their offering. , The X-ray detectors market ... technological advancements since its inception, such as a shift from ...
Breaking Medicine Technology:Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3Global X-Ray Detectors (Flat Panel, Computed Radiography, CCD, Line-Scan) Market - Forecast to 2019 2Global X-Ray Detectors (Flat Panel, Computed Radiography, CCD, Line-Scan) Market - Forecast to 2019 3
... , , ... KERX ) today announced results of the Open Label ... of elevated serum phosphorous levels, or hyperphosphatemia, in patients with ... in Taiwan, enrolled 29 of the 37 Taiwanese patients that ...
... , , , ... today announced results from a Phase II trial of regorafenib (BAY 73-4506), ... in a 31 percent partial response rate and 50 percent stabilization rate ... in an oral session at the joint 15th Congress of the European ...
Cached Medicine Technology:Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 2Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 3Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 4Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and easy ... treat specific body parts and muscle groups. , IsoComforter, ... use patented cold therapy machine with the innovative IsoTube design ... injuries. IsoComforter has become the industry leader in cold ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... anything but. Faced with health problems, financial issues and ... 65 years and older suffer from depression. While research ... problem, another group - centenarians - has been left largely ... hasn,t been studied thoroughly in this group," said Adam Davey, ...
... Shows Network Evening News and Newspapers Devote More Coverage to ... , , Health Was the ... Primary Season , , WASHINGTON, ... period of upheaval and transformation, a study from the Kaiser ...
... of ultrasound waves for deep vein thrombosis (DVT) may help ... alone, according to researchers at Emory University. The study will ... in New York City. , "These clots are a main ... quickly you can eliminate them the better," says Karthikeshwar Kasirajan, ...
... anti-viral drug developed by UT Southwestern Medical Center researchers, ... diseases, including potential bioterrorism agents. , In a ... Medicine , groups of guinea pigs infected with a ... fatal disease when treated with bavituximab alone or in ...
... INDIANAPOLIS, Nov. 23 Research professionals from the,health ... practice in which,to network, participate in continuing education ... within their organizations. , ... with which to partner when it became,apparent there ...
... in Palm Springs, California has recently completed work on a comprehensive ... the facility, but the overall recovery experience as well. , ... ... remodeling project, which took nearly a year and half to complete, ...
Cached Medicine News:Health News:Bittersweet milestones 2Health News:Wide-Ranging Study of National News Reveals Health News Comprises Less Than Four Percent of All Coverage 2Health News:Wide-Ranging Study of National News Reveals Health News Comprises Less Than Four Percent of All Coverage 3Health News:Wide-Ranging Study of National News Reveals Health News Comprises Less Than Four Percent of All Coverage 4Health News:Ultrasound waves aid in rapid treatment of DVT 2Health News:UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs 2Health News:Society of Insurance Research and Fletcher/CSI Create First Forum for Research Professionals in the Health Insurance Industry 2Health News:Society of Insurance Research and Fletcher/CSI Create First Forum for Research Professionals in the Health Insurance Industry 3Health News:California Drug Rehab Facility Completes Comprehensive Remodeling Project 2Health News:California Drug Rehab Facility Completes Comprehensive Remodeling Project 3
... Designed to accommodate a variety of applications ... the AMAX DestinyPlus is suitable for any ... environment. With a mixed-mode throughput exceeding 95 ... perform a full range of chromogenics, the ...
The TCM4 is able to detect patient changes and is portable....
The TCM400 is the first and only portable instrument to provide up to six simultaneous measurements of transcutaneous oxygen tension (tcpO2)...
... is the only online source of nationally ... critical care nurses and other healthcare professionals., ... so you can take them at your ... certificate is issued upon course completion. The ...
Medicine Products: